Journal of Hepatology
Volume 51, Issue 5 , Pages 939-948, November 2009

The long and winding road leading to the identification of the hepatitis C virus

  • Michael Houghton

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 510 289 0881; fax: +1 925 743 0660.

Epiphany Biosciences Inc., One California Street, Suite 2800 San Francisco, CA 94111, USA

published online 10 September 2009.

Associate Editor: M. Colombo

This review describes work conducted largely in my laboratory at the Chiron Corporation between 1982 and 1989 that led to the identification of the hepatitis C virus (HCV). Key colleagues included Dr. Qui-Lim Choo in my laboratory and Dr. George Kuo also of Chiron as well as my collaborator Dr. Daniel Bradley at the CDC who provided many biological samples from the NANBH chimpanzee model. Numerous molecular approaches were explored including the screening of tens of millions of bacterial cDNA clones derived from these materials. While this early genomics approach resulted in the identification of many host gene activities associated with NANBH, no genes of proven infectious etiology could be identified. A separate avenue of our research led to the molecular characterization of the complete hepatitis delta viral genome but unfortunately, this could not be used as a molecular handle for HCV. Largely following input from Dr. Kuo, I initiated a blind cDNA immunoscreening approach involving the large-scale screening of bacterial proteomic cDNA libraries derived from NANBH-infectious chimpanzee materials (prior to the development of PCR technology) using sera from NANBH patients as a presumptive source of viral antibodies. Eventually, this novel approach to identifying agents of infectious etiology led to the isolation of a single small cDNA clone that was proven to be derived from the HCV genome using various molecular and serological criteria. This discovery has facilitated the development of effective diagnostics, blood screening tests and the elucidation of promising drug and vaccine targets to control this global pathogen.

Keywords: Hepatitis C virus discovery, HCV history, Identification of HCV, Non-A, Non-B hepatitis NANBH

Abbreviations: HCV, hepatitis C virus, HAV, hepatitis A virus, HBV, hepatitis B virus, PCR, polymerase chain reaction, RT, reverse transcriptase, NANBH, Non-A, Non-B hepatitis, cDNA, complementary DNA, TFA, tubule-forming agent

 

 The author declared that he does not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00535-2

doi:10.1016/j.jhep.2009.08.004

Journal of Hepatology
Volume 51, Issue 5 , Pages 939-948, November 2009